Form 4 for OFIX Orthofix Medical Inc.
Accepted 2023-01-09 00:00:00 ET · period of report 2023-01-05 · accession 0001209191-23-002660 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-09 | 2023-01-05 | OFIX | Serbousek Jon Carl | Executive COB, Dir | A - Grant | $0.00 | +168.6K | 276.1K | +157% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-05 | A | A | 81,967 | $0.00 | 358,110 | D | — | — | (F3) Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025. (F4) Includes 307,621 unvested restricted stock units. |
| 2 | Common | Common Stock | 2023-01-05 | A | A | 45,872 | $0.00 | 235,379 | D | — | — | (F1) Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023. |
| 3 | Common | Common Stock | 2023-01-05 | A | A | 40,764 | $0.00 | 276,143 | D | — | — | (F2) Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024. |